Differences

This shows you the differences between two versions of the page.

--- home:diseases:hypertension [01.04.2019] – [Recent research] sallieq
+++ home:diseases:hypertension [03.24.2020] – [Recent research] sallieq
@@ Line 116: / Line 116: @@
 Olmesartan ameliorated arterial stiffness in patients with hypertension, which may be involved in the reduction of serum A-FABP.   (({{pubmed>long:21063874}}))
-Given the involvement of oxidative stress and its signaling in atherogenesis, and the available evidence of olmesartan's vasoprotective, anti-inflammatory and antiatherosclerotic effects derived from clinical trials in humans, the results of our study provide a mechanistic rationale for the omelsartan's antioxidant and anti-inflammatory potential translation, in the long term, toward the antiatherosclerotic and antiremodeling effects reported on the clinical ground.  (({{pubmed>long:21504378}}))
+Given the involvement of oxidative stress and its signaling in atherogenesis, and the available evidence of olmesartan's vasoprotective, anti-inflammatory and antiatherosclerotic effects derived from clinical trials in humans, the results of our study provide a mechanistic rationale for the olmesartan's antioxidant and anti-inflammatory potential translation, in the long term, toward the antiatherosclerotic and antiremodeling effects reported on the clinical ground.  (({{pubmed>long:21504378}}))
 {{tag>disease symptoms }}

home/diseases/hypertension.txt · Last modified: 09.14.2022 by 127.0.0.1